Invasive Candidiasis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Cidara Therapeutics Inc., Mundipharma, Astellas

Posted on
by

Invasive Candidiasis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Cidara Therapeutics Inc., Mundipharma, Astellas
The Invasive Candidiasis Market Forecast report offers an in-depth understanding of the Invasive Candidiasis, historical and forecasted epidemiology as well as the Invasive Candidiasis market trends in the 7MM.

DelveInsight’s “Invasive Candidiasis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Invasive Candidiasis, historical and forecasted epidemiology as well as the Invasive Candidiasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Invasive Candidiasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Invasive Candidiasis Market Forecast

 

Some of the key facts of the Invasive Candidiasis Market Report: 

  • The Invasive Candidiasis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In January 2024, Napp Pharmaceuticals’ latest antifungal remedy for invasive candidiasis, Rezzayo (rezafungin), has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Invasive candidiasis, a fungal infection triggered by the yeast candida, can impact critical bodily regions like the blood and vital organs.
  • In October 2023, Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) have revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion for rezafungin (rezafungin acetate) in the treatment of invasive candidiasis among adults.
  • According to a study by CDC [2020], candidemia is one of the most common bloodstream infections in the United States. During 2013–2017, the average incidence (rate of new infections) was approximately 9 per 100,000 people; however, this number varies substantially by geographic location and patient population
  • According to a study by Frederic et al. [2018], incidence of IC in the US cities dropped from 14.1 and 30.9 cases per 100 000 persons to 9.5 and 14.4/100 000, a decline of 33% and 54%, respectively, over the 5 year period between 2008 and 2013
  • Key Invasive Candidiasis Companies: Cidara Therapeutics Inc., Mundipharma, BREXAFEMME, Astellas Pharma, Pfizer, Gilead Sciences, Merck Sharp & Dohme, Vicuron Pharma, and others
  • Key Invasive Candidiasis Therapies: Rezafungin, Scynexis, Micafungin, Anidulafungin, AmBisome, Caspofungin, Fluconazole, and others
  • The Invasive Candidiasis epidemiology based on gender analyzed that pediatric and geriatric populations are more affected by Invasive Candidiasis than adults
  • The Invasive Candidiasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Invasive Candidiasis pipeline products will significantly revolutionize the Invasive Candidiasis market dynamics.

 

Invasive Candidiasis Overview

Invasive candidiasis is a serious fungal infection caused by the yeast Candida species, most commonly Candida albicans. It occurs when the Candida yeast enters the bloodstream and spreads throughout the body, affecting various organs and tissues. Invasive candidiasis can be life-threatening, particularly in individuals with weakened immune systems or underlying medical conditions.

 

Get a Free sample for the Invasive Candidiasis Market Report 

https://www.delveinsight.com/sample-request/invasive-candidiasis-market

 

Invasive Candidiasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Invasive Candidiasis Epidemiology Segmentation:

The Invasive Candidiasis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Invasive Candidiasis
  • Prevalent Cases of Invasive Candidiasis by severity
  • Gender-specific Prevalence of Invasive Candidiasis
  • Diagnosed Cases of Episodic and Chronic Invasive Candidiasis

 

Download the report to understand which factors are driving Invasive Candidiasis epidemiology trends @ Invasive Candidiasis Epidemiology Forecast

 

Invasive Candidiasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Invasive Candidiasis market or expected to get launched during the study period. The analysis covers Invasive Candidiasis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Invasive Candidiasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Invasive Candidiasis Therapies and Key Companies

  • Rezafungin: Cidara Therapeutics Inc./ Mundipharma
  • Scynexis: BREXAFEMME

 

Discover more about therapies set to grab major Invasive Candidiasis market share @ Invasive Candidiasis Treatment Market

 

Invasive Candidiasis Market Drivers

  • Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in invasive candidiasis .
  • The increasing prevalence of invasive candidiasis , for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

 

Invasive Candidiasis Market Unmet Needs

  • Challenges in diagnoses
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers

 

Scope of the Invasive Candidiasis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Invasive Candidiasis Companies: Cidara Therapeutics Inc., Mundipharma, BREXAFEMME, Astellas Pharma, Pfizer, Gilead Sciences, Merck Sharp & Dohme, Vicuron Pharma, and others
  • Key Invasive Candidiasis Therapies: Rezafungin, Scynexis, Micafungin, Anidulafungin, AmBisome, Caspofungin, Fluconazole, and others
  • Invasive Candidiasis Therapeutic Assessment: Invasive Candidiasis current marketed and Invasive Candidiasis emerging therapies
  • Invasive Candidiasis Market Dynamics: Invasive Candidiasis market drivers and Invasive Candidiasis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Invasive Candidiasis Unmet Needs, KOL’s views, Analyst’s views, Invasive Candidiasis Market Access and Reimbursement 

 

To know more about Invasive Candidiasis companies working in the treatment market, visit @ Invasive Candidiasis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Invasive Candidiasis Market Report Introduction

2. Executive Summary for Invasive Candidiasis

3. SWOT analysis of Invasive Candidiasis

4. Invasive Candidiasis Patient Share (%) Overview at a Glance

5. Invasive Candidiasis Market Overview at a Glance

6. Invasive Candidiasis Disease Background and Overview

7. Invasive Candidiasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Invasive Candidiasis 

9. Invasive Candidiasis Current Treatment and Medical Practices

10. Invasive Candidiasis Unmet Needs

11. Invasive Candidiasis Emerging Therapies

12. Invasive Candidiasis Market Outlook

13. Country-Wise Invasive Candidiasis Market Analysis (2019–2032)

14. Invasive Candidiasis Market Access and Reimbursement of Therapies

15. Invasive Candidiasis Market Drivers

16. Invasive Candidiasis Market Barriers

17.  Invasive Candidiasis Appendix

18. Invasive Candidiasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/